UKHSA COVID-19 National Epidemiology Cell, London, UK.
UKHSA Genomics and Public Health Analysis, London, UK.
Influenza Other Respir Viruses. 2023 May;17(5):e13150. doi: 10.1111/irv.13150.
There are concerns that sotrovimab has reduced efficacy at reducing hospitalisation risk against the BA.2 sub-lineage of the Omicron SARS-CoV-2 variant. We performed a retrospective cohort (n = 8850) study of individuals treated with sotrovimab in the community, with the objective of assessing whether there were any differences in risk of hospitalisation of BA.2 cases compared with BA.1. We estimated that the hazard ratio of hospital admission with a length of stay of 2 days or more was 1.17 for BA.2 compared with BA.1 (95%CI 0.74-1.86). These results suggest that the risk of hospital admission was similar between the two sub-lineages.
人们担心索特罗维单抗降低了对奥密克戎 SARS-CoV-2 变异株 BA.2 亚谱系的住院风险的疗效。我们对在社区中接受索特罗维单抗治疗的个体进行了一项回顾性队列（n=8850）研究，目的是评估 BA.2 病例与 BA.1 相比，住院风险是否存在差异。我们估计住院时间为 2 天或以上的住院入院风险比为 1.17（95%CI 0.74-1.86）。这些结果表明，两种亚谱系之间的住院风险相似。
